Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer

• Status: Recruiting
• Trial end date: 2027-02-02
• Target enrollment: 0
• Participant gender: Male

Summary

This is a prospective, open, randomized phase II trial.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Regina Elena Cancer Institute
• Treatments: Triptorelin Pamoate

Criteria

Inclusion Criteria:

• Histologically proven prostate adenocarcinoma

• IR or HR in the NCCN definition

• N0M0 at staging with choline or (preferably) PSMA PET-CT;

• ECOG performance status between 0 and 2;

Exclusion Criteria:

• Previous local treatment of the prostate with surgery (radical prostatectomy or cryotherapy)

• Previous radiotherapy to the pelvis

• Previous chemotherapy for malignancy in past 5 years

• Impossibility to implant fiducials for tracking purposes

• Impossibility to undergo MRI of the prostate

• Contraindication to short term AD

• Prostate volume >90cc